The complexity of the Nrf2 pathway: Beyond the antioxidant response

Journal of Nutritional Biochemistry

Volumn 26, Issue 12, 2015, Pages 1401-1413

  Huang, Ying ^a   Li, Wenji ^a   Su, Zheng yuan ^a   Kong, Ah Ng Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Activator; Antioxidant; Kelch like ECH associated protein 1 (Keap1); NF E2 related factor 2 (Nrf2); Nutrients; ROS

Indexed keywords

ACTIN; ARSENIC TRIOXIDE; BETA CADHERIN; CADHERIN; CALMODULIN; CURCUMIN; GENISTEIN; GLUTATHIONE TRANSFERASE; GLYCOGEN SYNTHASE KINASE 3; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; OLTIPRAZ; PHOSPHATIDYLINOSITOL 3 KINASE; PKR LIKE ENDOPLASMIC RETICULUM KINASE; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN P21; PROTEIN P62; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); STRESS ACTIVATED PROTEIN KINASE 1; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; ANTIOXIDANT; GUANOSINE TRIPHOSPHATASE; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; XENOBIOTIC AGENT;

ADVANCED CANCER; ANTIOXIDANT ACTIVITY; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DEGENERATIVE DISEASE; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; LUNG INJURY; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; XENOBIOTIC METABOLISM; ANIMAL; CHRONIC DISEASE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; INFLAMMATION; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION; PHYSIOLOGICAL STRESS; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIOXIDANTS; CHRONIC DISEASE; DRUG RESISTANCE; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GTP PHOSPHOHYDROLASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; XENOBIOTICS;

EID: 84983150554     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.08.001     Document Type: Review

References (246)

1. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236:313-322.
2. McMahon M., Itoh K., Yamamoto M., Chanas S.A., Henderson C.J., McLellan L.I., et al. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 2001, 61:3299-3307.
3. Iida K., Itoh K., Kumagai Y., Oyasu R., Hattori K., Kawai K., et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004, 64:6424-6431.
4. Ramos-Gomez M., Kwak M.K., Dolan P.M., Itoh K., Yamamoto M., Talalay P., et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 2001, 98:3410-3415.
5. Kwak M.K., Kensler T.W. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 2010, 244:66-76.
6. Chen P.C., Vargas M.R., Pani A.K., Smeyne R.J., Johnson D.A., Kan Y.W., et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci U S A 2009, 106:2933-2938.
7. Li J., Zhang C., Xing Y., Janicki J.S., Yamamoto M., Wang X.L., et al. Up-regulation of p27(kip1) contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy. Cardiovasc Res 2011, 90:315-324.
8. Biswal S., Thimmulappa R.K., Harvey C.J. Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD. Proc Am Thorac Soc 2012, 9:47-51.
9. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol Res 2008, 58:262-270.
10. Prestera T., Holtzclaw W.D., Zhang Y., Talalay P. Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci U S A 1993, 90:2965-2969.
11. Moi P., Chan K., Asunis I., Cao A., Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 1994, 91:9926-9930.
12. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999, 13:76-86.
13. Dhakshinamoorthy S., Jaiswal A.K. Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 2001, 20:3906-3917.
14. Rushmore T.H., Morton M.R., Pickett C.B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 1991, 266:11632-11639.
15. Eggler A.L., Luo Y., van Breemen R.B., Mesecar A.D. Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. Chem Res Toxicol 2007, 20:1878-1884.
16. Hu C., Eggler A.L., Mesecar A.D., van Breemen R.B. Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol 2011, 24:515-521.
17. Zhang D.D., Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 2003, 23:8137-8151.
18. Jakubikova J., Sedlak J., Mithen R., Bao Y. Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 2005, 69:1543-1552.
19. Zhang C., Su Z.Y., Khor T.O., Shu L., Kong A.N. Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochem Pharmacol 2013, 85:1398-1404.
20. Su Z.Y., Zhang C., Lee J.H., Shu L., Wu T.Y., Khor T.O., et al. Requirement and epigenetics reprogramming of Nrf2 in suppression of tumor promoter TPA-induced mouse skin cell transformation by sulforaphane. Cancer Prev Res 2014, 7:319-329.
21. Khor T.O., Huang Y., Wu T.Y., Shu L., Lee J., Kong A.N. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem Pharmacol 2011, 82:1073-1078.
22. Farombi E.O., Shrotriya S., Na H.-K., Kim S.-H., Surh Y.-J. Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem Toxicol 2008, 46:1279-1287.
23. Wu J., Li Q., Wang X., Yu S., Li L., Wu X., et al. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. PLoS One 2013, 8:e59843.
24. Kim S., Lee H.G., Park S.A., Kundu J.K., Keum Y.S., Cha Y.N., et al. Keap1 cysteine 288 as a potential target for diallyl trisulfide-induced Nrf2 activation. PLoS One 2014, 9:e85984.
25. Tsai C.Y., Wang C.C., Lai T.Y., Tsu H.N., Wang C.H., Liang H.Y., et al. Antioxidant effects of diallyl trisulfide on high glucose-induced apoptosis are mediated by the PI3K/Akt-dependent activation of Nrf2 in cardiomyocytes. Int J Cardiol 2013, 168:1286-1297.
26. Kanzaki H., Shinohara F., Itohiya-Kasuya K., Ishikawa M., Nakamura Y. Nrf2 activation attenuates both orthodontic tooth movement and relapse. J Dent Res 2015, 94:787-794.
27. Wang Y., Liu N., Su X., Zhou G., Sun G., Du F., et al. Epigallocatechin-3-gallate attenuates transforming growth factor-beta1 induced epithelial-mesenchymal transition via Nrf2 regulation in renal tubular epithelial cells. Biomed Pharmacother 2015, 70:260-267.
28. Yang G.Z., Wang Z.J., Bai F., Qin X.J., Cao J., Lv J.Y., et al. Epigallocatechin-3-Gallate protects HUVECs from PM2.5-induced oxidative stress injury by activating critical antioxidant pathways. Molecules 2015, 20:6626-6639.
29. Jiang J., Mo Z.C., Yin K., Zhao G.J., Lv Y.C., Ouyang X.P., et al. Epigallocatechin-3-gallate prevents TNF-alpha-induced NF-kappaB activation thereby upregulating ABCA1 via the Nrf2/Keap1 pathway in macrophage foam cells. Int J Mol Med 2012, 29:946-956.
30. Na H.K., Kim E.H., Jung J.H., Lee H.H., Hyun J.W., Surh Y.J. (-)-Epigallocatechin gallate induces Nrf2-mediated antioxidant enzyme expression via activation of PI3K and ERK in human mammary epithelial cells. Arch Biochem Biophys 2008, 476:171-177.
31. Wang R., Tu J., Zhang Q., Zhang X., Zhu Y., Ma W., et al. Genistein attenuates ischemic oxidative damage and behavioral deficits via eNOS/Nrf2/HO-1 signaling. Hippocampus 2013, 23:634-647.
32. Xi Y.D., Yu H.L., Ding J., Ma W.W., Yuan L.H., Feng J.F., et al. Flavonoids protect cerebrovascular endothelial cells through Nrf2 and PI3K from beta-amyloid peptide-induced oxidative damage. Curr Neurovasc Res 2012, 9:32-41.
33. Liby K., Hock T., Yore M.M., Suh N., Place A.E., Risingsong R., et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005, 65:4789-4798.
34. Takaya K., Suzuki T., Motohashi H., Onodera K., Satomi S., Kensler T.W., et al. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 2012, 53:817-827.
35. Eggler A.L., Small E., Hannink M., Mesecar A.D. Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1. Biochem J 2009, 422:171-180.
36. Wakabayashi N., Dinkova-Kostova A.T., Holtzclaw W.D., Kang M.I., Kobayashi A., Yamamoto M., et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A 2004, 101:2040-2045.
37. Abiko Y., Miura T., Phuc B.H., Shinkai Y., Kumagai Y. Participation of covalent modification of Keap1 in the activation of Nrf2 by tert-butylbenzoquinone, an electrophilic metabolite of butylated hydroxyanisole. Toxicol Appl Pharmacol 2011, 255:32-39.
38. Yamamoto T., Suzuki T., Kobayashi A., Wakabayashi J., Maher J., Motohashi H., et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008, 28:2758-2770.
39. Hong F., Sekhar K.R., Freeman M.L., Liebler D.C. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J Biol Chem 2005, 280:31768-31775.
40. Yu R., Tan T.H., Kong A.N. Butylated hydroxyanisole and its metabolite tert-butylhydroquinone differentially regulate mitogen-activated protein kinases. The role of oxidative stress in the activation of mitogen-activated protein kinases by phenolic antioxidants. J Biol Chem 1997, 272:28962-28970.
41. He X., Chen M.G., Lin G.X., Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 x Keap1 x Cul3 complex and recruiting Nrf2 x Maf to the antioxidant response element enhancer. J Biol Chem 2006, 281:23620-23631.
42. Wang X.J., Sun Z., Chen W., Li Y., Villeneuve N.F., Zhang D.D. Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. Toxicol Appl Pharmacol 2008, 230:383-389.
43. He X., Ma Q. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol Exp Ther 2010, 332:66-75.
44. Lau A., Zheng Y., Tao S., Wang H., Whitman S.A., White E., et al. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. Mol Cell Biol 2013, 33:2436-2446.
45. McMahon M., Itoh K., Yamamoto M., Hayes J.D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003, 278:21592-21600.
46. Kobayashi A., Kang M.I., Okawa H., Ohtsuji M., Zenke Y., Chiba T., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004, 24:7130-7139.
47. McMahon M., Thomas N., Itoh K., Yamamoto M., Hayes J.D. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem 2006, 281:24756-24768.
48. Tong K.I., Katoh Y., Kusunoki H., Itoh K., Tanaka T., Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 2006, 26:2887-2900.
49. Zhang D.D., Lo S.C., Cross J.V., Templeton D.J., Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004, 24:10941-10953.
50. Furukawa M., Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005, 25:162-171.
51. Wakabayashi N., Itoh K., Wakabayashi J., Motohashi H., Noda S., Takahashi S., et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 2003, 35:238-245.
52. Suzuki T., Maher J., Yamamoto M. Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo. Cancer Res 2011, 71:1700-1709.
53. Dinkova-Kostova A.T., Holtzclaw W.D., Cole R.N., Itoh K., Wakabayashi N., Katoh Y., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 2002, 99:11908-11913.
54. Suzuki T., Motohashi H., Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 2013, 34:340-346.
55. McMahon M., Lamont D.J., Beattie K.A., Hayes J.D. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A 2010, 107:18838-18843.
56. Eggler A.L., Liu G., Pezzuto J.M., van Breemen R.B., Mesecar A.D. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci U S A 2005, 102:10070-10075.
57. Nguyen T., Sherratt P.J., Nioi P., Yang C.S., Pickett C.B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 2005, 280:32485-32492.
58. Hayes J.D., McMahon M., Chowdhry S., Dinkova-Kostova A.T. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010, 13:1713-1748.
59. Huang H.C., Nguyen T., Pickett C.B. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci U S A 2000, 97:12475-12480.
60. Sun Z., Huang Z., Zhang D.D. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One 2009, 4:e6588.
61. Numazawa S., Ishikawa M., Yoshida A., Tanaka S., Yoshida T. Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol Cell Physiol 2003, 285:C334-C342.
62. Bloom D.A., Jaiswal A.K. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 2003, 278:44675-44682.
63. Lee J.H., Khor T.O., Shu L., Su Z.Y., Fuentes F., Kong A.N. Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther 2013, 137:153-171.
64. Cullinan S.B., Diehl J.A. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem 2004, 279:20108-20117.
65. Kang K.W., Lee S.J., Park J.W., Kim S.G. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 2002, 62:1001-1010.
66. Jain A.K., Jaiswal A.K. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem 2007, 282:16502-16510.
67. Rada P., Rojo A.I., Chowdhry S., McMahon M., Hayes J.D., Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 2011, 31:1121-1133.
68. Chowdhry S., Zhang Y., McMahon M., Sutherland C., Cuadrado A., Hayes J.D. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 2013, 32:3765-3781.
69. Rojo A.I., Sagarra M.R., Cuadrado A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 2008, 105:192-202.
70. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005, 171:603-614.
71. Komatsu M., Kurokawa H., Waguri S., Taguchi K., Kobayashi A., Ichimura Y., et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010, 12:213-223.
72. Copple I.M., Lister A., Obeng A.D., Kitteringham N.R., Jenkins R.E., Layfield R., et al. Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J Biol Chem 2010, 285:16782-16788.
73. Lau A., Wang X.J., Zhao F., Villeneuve N.F., Wu T., Jiang T., et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 2010, 30:3275-3285.
74. Jain A., Lamark T., Sjottem E., Larsen K.B., Awuh J.A., Overvatn A., et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 2010, 285:22576-22591.
75. Taguchi K., Fujikawa N., Komatsu M., Ishii T., Unno M., Akaike T., et al. Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci U S A 2012, 109:13561-13566.
76. Inami Y., Waguri S., Sakamoto A., Kouno T., Nakada K., Hino O., et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 2011, 193:275-284.
77. Komatsu M., Waguri S., Koike M., Sou Y.S., Ueno T., Hara T., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
78. Chen W., Sun Z., Wang X.J., Jiang T., Huang Z., Fang D., et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 2009, 34:663-673.
79. Kim J.H., Xu E.Y., Sacks D.B., Lee J., Shu L., Xia B., et al. Identification and functional studies of a new Nrf2 partner IQGAP1: a critical role in the stability and transactivation of Nrf2. Antioxid Redox Signal 2013, 19:89-101.
80. Cheung K.L., Lee J.H., Shu L., Kim J.H., Sacks D.B., Kong A.N. The Ras GTPase-activating-like protein IQGAP1 mediates Nrf2 protein activation via the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK pathway. J Biol Chem 2013, 288:22378-22386.
81. Briggs M.W., Sacks D.B. IQGAP1 as signal integrator: Ca2+, calmodulin, Cdc42 and the cytoskeleton. FEBS Lett 2003, 542:7-11.
82. Roy M., Li Z., Sacks D.B. IQGAP1 binds ERK2 and modulates its activity. J Biol Chem 2004, 279:17329-17337.
83. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
84. Li W., Thakor N., Xu E.Y., Huang Y., Chen C., Yu R., et al. An internal ribosomal entry site mediates redox-sensitive translation of Nrf2. Nucleic Acids Res 2010, 38:778-788.
85. Ghavifekr Fakhr M., Farshdousti Hagh M., Shanehbandi D., Baradaran B. DNA methylation pattern as important epigenetic criterion in cancer. Genet Res Int 2013, 2013:317569.
86. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
87. Issa J.P., Kantarjian H.M. Targeting DNA methylation. Clin Cancer Res 2009, 15:3938-3946.
88. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4:143-153.
89. Arasaradnam R.P., Commane D.M., Bradburn D., Mathers J.C. A review of dietary factors and its influence on DNA methylation in colorectal carcinogenesis. Epigenetics 2008, 3:193-198.
90. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
91. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
92. Yu S., Khor T.O., Cheung K.L., Li W., Wu T.Y., Huang Y., et al. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 2010, 5:e8579.
93. Huang Y., Khor T.O., Shu L., Saw C.L., Wu T.Y., Suh N., et al. A gamma-tocopherol-rich mixture of tocopherols maintains Nrf2 expression in prostate tumors of TRAMP mice via epigenetic inhibition of CpG methylation. J Nutr 2012, 142:818-823.
94. Wu T.Y., Khor T.O., Su Z.Y., Saw C.L., Shu L., Cheung K.L., et al. Epigenetic modifications of Nrf2 by 3,3'-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. AAPS J 2013, 15:864-874.
95. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
96. Narasimhan M., Patel D., Vedpathak D., Rathinam M., Henderson G., Mahimainathan L. Identification of novel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal, SH-SY5Y cells. PLoS One 2012, 7:e51111.
97. Sangokoya C., Telen M.J., Chi J.T. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 2010, 116:4338-4348.
98. Yang M., Yao Y., Eades G., Zhang Y., Zhou Q. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res Treat 2011, 129:983-991.
99. Li N., Muthusamy S., Liang R., Sarojini H., Wang E. Increased expression of miR-34a and miR-93 in rat liver during aging, and their impact on the expression of Mgst1 and Sirt1. Mech Ageing Dev 2011, 132:75-85.
100. Eades G., Yang M., Yao Y., Zhang Y., Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 2011, 286:40725-40733.
101. Bryan H.K., Olayanju A., Goldring C.E., Park B.K. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 2013, 85:705-717.
102. Keum Y.S., Jeong W.S., Kong A.N. Chemopreventive functions of isothiocyanates. Drug News Perspect 2005, 18:445-451.
103. Ho C.Y., Cheng Y.T., Chau C.F., Yen G.C. Effect of diallyl sulfide on in vitro and in vivo Nrf2-mediated pulmonic antioxidant enzyme expression via activation ERK/p38 signaling pathway. J Agric Food Chem 2012, 60:100-107.
104. Perez Diaz M.F., Acosta M., Mohamed F.H., Ferramola M.L., Oliveros L.B., Gimenez M.S. Protective effect of soybeans as protein source in the diet against cadmium-aorta redox and morphological alteration. Toxicol Appl Pharmacol 2013, 272:806-815.
105. Lin H., Wei B., Li G., Zheng J., Sun J., Chu J., et al. Sulforaphane reverses glucocorticoid-induced apoptosis in osteoblastic cells through regulation of the Nrf2 pathway. Drug Des Devel Ther 2014, 8:973-982.
106. Das L., Vinayak M. Long term effect of curcumin in restoration of tumour suppressor p53 and phase-ii antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer. PLoS One 2015, 10:e0124000. 10.1371/journal.pone.0124000.
107. Balstad T.R., Carlsen H., Myhrstad M.C., Kolberg M., Reiersen H., Gilen L., et al. Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo - studies in electrophile response element transgenic mice. Mol Nutr Food Res 2011, 55:185-197.
108. Tsai P.Y., Ka S.M., Chang J.M., Chen H.C., Shui H.A., Li C.Y., et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 2011, 51:744-754.
109. Zhang Z.M., Yang X.Y., Yuan J.H., Sun Z.Y., Li Y.Q. Modulation of NRF2 and UGT1A expression by epigallocatechin-3-gallate in colon cancer cells and BALB/c mice. Chin Med J 2009, 122:1660-1665.
110. Kobayashi M., Li L., Iwamoto N., Nakajima-Takagi Y., Kaneko H., Nakayama Y., et al. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 2009, 29:493-502.
111. Hu R., Xu C., Shen G., Jain M.R., Khor T.O., Gopalkrishnan A., et al. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett 2006, 243:170-192.
112. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002, 62:5196-5203.
113. Khor T.O., Hu R., Shen G., Jeong W.S., Hebbar V., Chen C., et al. Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. Biopharm Drug Dispos 2006, 27:407-420.
114. Xu C., Huang M.T., Shen G., Yuan X., Lin W., Khor T.O., et al. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 2006, 66:8293-8296.
115. Nair S., Barve A., Khor T.O., Shen G.X., Lin W., Chan J.Y., et al. Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 2010, 31:1223-1240.
116. Keum Y.S., Khor T.O., Lin W., Shen G., Kwon K.H., Barve A., et al. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res 2009, 26:2324-2331.
117. Wang H., Khor T.O., Yang Q., Huang Y., Wu T.Y., Saw C.L., et al. Pharmacokinetics and pharmacodynamics of phase II drug metabolizing/antioxidant enzymes gene response by anticancer agent sulforaphane in rat lymphocytes. Mol Pharm 2012, 9:2819-2827.
118. Kensler T.W., Egner P.A., Agyeman A.S., Visvanathan K., Groopman J.D., Chen J.G., et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 2013, 329:163-177.
119. Shapiro T.A., Fahey J.W., Dinkova-Kostova A.T., Holtzclaw W.D., Stephenson K.K., Wade K.L., et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 2006, 55:53-62.
120. Egner P.A., Chen J.G., Wang J.B., Wu Y., Sun Y., Lu J.H., et al. Bioavailability of Sulforaphane from two broccoli sprout beverages: results of a short-term, cross-over clinical trial in Qidong, China. Cancer Prev Res (Phila) 2011, 4:384-395.
121. Kensler T.W., Ng D., Carmella S.G., Chen M., Jacobson L.P., Munoz A., et al. Modulation of the metabolism of airborne pollutants by glucoraphanin-rich and sulforaphane-rich broccoli sprout beverages in Qidong, China. Carcinogenesis 2012, 33:101-107.
122. Trujillo J., Chirino Y.I., Molina-Jijon E., Anderica-Romero A.C., Tapia E., Pedraza-Chaverri J. Renoprotective effect of the antioxidant curcumin: recent findings. Redox Biol 2013, 1:448-456.
123. Scapagnini G., Vasto S., Abraham N.G., Caruso C., Zella D., Fabio G. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 2011, 44:192-201.
124. Suganuma M., Okabe S., Sueoka N., Sueoka E., Matsuyama S., Imai K., et al. Green tea and cancer chemoprevention. Mutat Res 1999, 428:339-344.
125. Thimmulappa R.K., Fuchs R.J., Malhotra D., Scollick C., Traore K., Bream J.H., et al. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid Redox Signal 2007, 9:1963-1970.
126. Liby K.T., Yore M.M., Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007, 7:357-369.
127. Yates M.S., Tran Q.T., Dolan P.M., Osburn W.O., Shin S., McCulloch C.C., et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009, 30:1024-1031.
128. Liby K.T., Sporn M.B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012, 64:972-1003.
129. Sussan T.E., Rangasamy T., Blake D.J., Malhotra D., El-Haddad H., Bedja D., et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci U S A 2009, 106:250-255.
130. Liu M., Reddy N.M., Higbee E.M., Potteti H.R., Noel S., Racusen L., et al. The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney Int 2014, 85:134-141.
131. Kensler T.W., Groopman J.D., Sutter T.R., Curphey T.J., Roebuck B.D. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol 1999, 12:113-126.
132. Jia Z., Zhu H., Trush M.A., Misra H.P., Li Y. Generation of superoxide from reaction of 3H-1,2-dithiole-3-thione with thiols: implications for dithiolethione chemoprotection. Mol Cell Biochem 2008, 307:185-191.
133. Velayutham M., Villamena F.A., Navamal M., Fishbein J.C., Zweier J.L. Glutathione-mediated formation of oxygen free radicals by the major metabolite of oltipraz. Chem Res Toxicol 2005, 18:970-975.
134. Holland R., Navamal M., Velayutham M., Zweier J.L., Kensler T.W., Fishbein J.C. Hydrogen peroxide is a second messenger in phase 2 enzyme induction by cancer chemopreventive dithiolethiones. Chem Res Toxicol 2009, 22:1427-1434.
135. Ramos-Gomez M., Dolan P.M., Itoh K., Yamamoto M., Kensler T.W. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 2003, 24:461-467.
136. Buetler T.M., Gallagher E.P., Wang C., Stahl D.L., Hayes J.D., Eaton D.L. Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Toxicol Appl Pharmacol 1995, 135:45-57.
137. Wattenberg L.W., Bueding E. Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. Carcinogenesis 1986, 7:1379-1381.
138. Kensler T.W., Egner P.A., Trush M.A., Bueding E., Groopman J.D. Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 1985, 6:759-763.
139. Helzlsouer K.J., Kensler T.W. Cancer chemoprotection by oltipraz: experimental and clinical considerations. Prev Med 1993, 22:783-795.
140. Kensler T.W., Egner P.A., Dolan P.M., Groopman J.D., Roebuck B.D. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 1987, 47:4271-4277.
141. Zhang Y., Munday R. Dithiolethiones for cancer chemoprevention: where do we stand?. Mol Cancer Ther 2008, 7:3470-3479.
142. Wang J.S., Shen X., He X., Zhu Y.R., Zhang B.C., Wang J.B., et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999, 91:347-354.
143. Nair S., Xu C., Shen G., Hebbar V., Gopalakrishnan A., Hu R., et al. Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Pharm Res 2006, 23:2621-2637.
144. Wang X.J., Hayes J.D., Higgins L.G., Wolf C.R., Dinkova-Kostova A.T. Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones. Chem Biol 2010, 17:75-85.
145. Dinkova-Kostova A.T., Wang X.J. Induction of the Keap1/Nrf2/ARE pathway by oxidizable diphenols. Chem Biol Interact 2011, 192:101-106.
146. Rao M.S., Lalwani N.D., Watanabe T.K., Reddy J.K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res 1984, 44:1072-1076.
147. Kahl R. Synthetic antioxidants: biochemical actions and interference with radiation, toxic compounds, chemical mutagens and chemical carcinogens. Toxicology 1984, 33:185-228.
148. Hirose M., Takesada Y., Tanaka H., Tamano S., Kato T., Shirai T. Carcinogenicity of antioxidants BHA, caffeic acid, sesamol, 4-methoxyphenol and catechol at low doses, either alone or in combination, and modulation of their effects in a rat medium-term multi-organ carcinogenesis model. Carcinogenesis 1998, 19:207-212.
149. Jiang T., Huang Z., Chan J.Y., Zhang D.D. Nrf2 protects against As(III)-induced damage in mouse liver and bladder. Toxicol Appl Pharmacol 2009, 240:8-14.
150. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
151. Hayes J.D., McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009, 34:176-188.
152. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005, 28:249-268.
153. Nebert D.W., Shi Z., Galvez-Peralta M., Uno S., Dragin N. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences--Cyp1 knockout mouse lines as a paradigm. Mol Pharmacol 2013, 84:304-313.
154. Eaton D.L., Gallagher E.P. Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 1994, 34:135-172.
155. Bosma-den Boer M.M., van Wetten M.L., Pruimboom L. Chronic inflammatory diseases are stimulated by current lifestyle: how diet, stress levels and medication prevent our body from recovering. Nutr Metab 2012, 9:1-14.
156. Berk M., Williams L.J., Jacka F.N., O'Neil A., Pasco J.A., Moylan S., et al. So depression is an inflammatory disease, but where does the inflammation come from?. BMC Med 2013, 11:201-216.
157. Chen X.L., Kunsch C. Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr Pharm Des 2004, 10:879-891.
158. Yang H., Magilnick N., Ou X., Lu S.C. Tumour necrosis factor alpha induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor kappaB and activator protein-1. Biochem J 2005, 391:399-408.
159. Chen X.L., Dodd G., Thomas S., Zhang X., Wasserman M.A., Rovin B.H., et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006, 290:H1862-H1870.
160. Khor T.O., Huang M.T., Kwon K.H., Chan J.Y., Reddy B.S., Kong A.N. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006, 66:11580-11584.
161. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006, 3:e420.
162. Rahman I., Biswas S.K., Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006, 72:1439-1452.
163. Yates M.S., Kensler T.W. Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect 2007, 20:109-117.
164. Cho H.Y., Reddy S.P., Yamamoto M., Kleeberger S.R. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004, 18:1258-1260.
165. Ishii Y., Itoh K., Morishima Y., Kimura T., Kiwamoto T., Iizuka T., et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol 2005, 175:6968-6975.
166. Rangasamy T., Cho C.Y., Thimmulappa R.K., Zhen L., Srisuma S.S., Kensler T.W., et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004, 114:1248-1259.
167. Rangasamy T., Guo J., Mitzner W.A., Roman J., Singh A., Fryer A.D., et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 2005, 202:47-59.
168. Thimmulappa R.K., Lee H., Rangasamy T., Reddy S.P., Yamamoto M., Kensler T.W., et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006, 116:984-995.
169. Thimmulappa R.K., Scollick C., Traore K., Yates M., Trush M.A., Liby K.T., et al. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem Biophys Res Commun 2006, 351:883-889.
170. Lin W., Wu R.T., Wu T., Khor T.O., Wang H., Kong A.N. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol 2008, 76:967-973.
171. Heiss E., Herhaus C., Klimo K., Bartsch H., Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001, 276:32008-32015.
172. Khor T.O., Yu S., Kong A.N. Dietary cancer chemopreventive agents - targeting inflammation and Nrf2 signaling pathway. Planta Med 2008, 74:1540-1547.
173. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986, 47:921-928.
174. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009, 1:1-10.
175. Inoue J., Kerr L.D., Kakizuka A., Verma I.M. I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell 1992, 68:1109-1120.
176. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
177. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663.
178. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288.
179. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995, 14:2876-2883.
180. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med 2010, 49:1603-1616.
181. Liu G.H., Qu J., Shen X. NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim Biophys Acta 1783, 2008:713-727.
182. Hirota K., Murata M., Sachi Y., Nakamura H., Takeuchi J., Mori K., et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 1999, 274:27891-27897.
183. Jun C.D., Kim Y., Choi E.Y., Kim M., Park B., Youn B., et al. Gliotoxin reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice: evidence of the connection between heme oxygenase-1 and the nuclear factor-kappaB pathway in vitro and in vivo. Inflamm Bowel Dis 2006, 12:619-629.
184. Iskander K., Li J., Han S., Zheng B., Jaiswal A.K. NQO1 and NQO2 regulation of humoral immunity and autoimmunity. J Biol Chem 2006, 281:30917-30924.
185. Seldon M.P., Silva G., Pejanovic N., Larsen R., Gregoire I.P., Filipe J., et al. Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of NF-kappaB RelA phosphorylation at serine 276. J Immunol 2007, 179:7840-7851.
186. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001, 31:469-497.
187. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
188. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007, 446:749-757.
189. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92:1295-1302.
190. Vollrath V., Wielandt A.M., Iruretagoyena M., Chianale J. Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem J 2006, 395:599-609.
191. Ji L., Li H., Gao P., Shang G., Zhang D.D., Zhang N., et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One 2013, 8:e63404.
192. Singh A., Wu H., Zhang P., Happel C., Ma J., Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 2010, 9:2365-2376.
193. Maher J.M., Dieter M.Z., Aleksunes L.M., Slitt A.L., Guo G., Tanaka Y., et al. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology 2007, 46:1597-1610.
194. Hirotsu Y., Katsuoka F., Funayama R., Nagashima T., Nishida Y., Nakayama K., et al. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res 2012, 40:10228-10239.
195. Maher J.M., Cheng X., Slitt A.L., Dieter M.Z., Klaassen C.D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 2005, 33:956-962.
196. Adachi T., Nakagawa H., Chung I., Hagiya Y., Hoshijima K., Noguchi N., et al. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol 2007, 6:335-348.
197. Yeh C.T., Yen G.C. Induction of hepatic antioxidant enzymes by phenolic acids in rats is accompanied by increased levels of multidrug resistance-associated protein 3 mRNA expression. J Nutr 2006, 136:11-15.
198. Anwar-Mohamed A., Degenhardt O.S., El Gendy M.A., Seubert J.M., Kleeberger S.R., El-Kadi A.O. The effect of Nrf2 knockout on the constitutive expression of drug metabolizing enzymes and transporters in C57Bl/6 mice livers. Toxicol In Vitro 2011, 25:785-795.
199. Kweon M.H., Adhami V.M., Lee J.S., Mukhtar H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 2006, 281:33761-33772.
200. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243.
201. Homma S., Ishii Y., Morishima Y., Yamadori T., Matsuno Y., Haraguchi N., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009, 15:3423-3432.
202. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008, 105:13568-13573.
203. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
204. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
205. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
206. Mitsuishi Y., Taguchi K., Kawatani Y., Shibata T., Nukiwa T., Aburatani H., et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012, 22:66-79.
207. Kinch L., Grishin N.V., Brugarolas J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 2011, 20:418-420.
208. Adam J., Hatipoglu E., O'Flaherty L., Ternette N., Sahgal N., Lockstone H., et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011, 20:524-537.
209. Ashrafian H., Czibik G., Bellahcene M., Aksentijevic D., Smith A.C., Mitchell S.J., et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab 2012, 15:361-371.
210. Sudarshan S., Sourbier C., Kong H.S., Block K., Valera Romero V.A., Yang Y., et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009, 29:4080-4090.
211. Primiano T., Egner P.A., Sutter T.R., Kelloff G.J., Roebuck B.D., Kensler T.W. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res 1995, 55:4319-4324.
212. Fahey J.W., Zhang Y., Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A 1997, 94:10367-10372.
213. Fahey J.W., Haristoy X., Dolan P.M., Kensler T.W., Scholtus I., Stephenson K.K., et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002, 99:7610-7615.
214. Osburn W.O., Karim B., Dolan P.M., Liu G., Yamamoto M., Huso D.L., et al. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer 2007, 121:1883-1891.
215. Clark J., Simon D.K. Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2009, 11:509-528.
216. Innamorato N.G., Jazwa A., Rojo A.I., Garcia C., Fernandez-Ruiz J., Grochot-Przeczek A., et al. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 2010, 5:e11838.
217. Jakel R.J., Townsend J.A., Kraft A.D., Johnson J.A. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007, 1144:192-201.
218. Rojo A.I., Innamorato N.G., Martin-Moreno A.M., De Ceballos M.L., Yamamoto M., Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010, 58:588-598.
219. Kanninen K., Heikkinen R., Malm T., Rolova T., Kuhmonen S., Leinonen H., et al. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2009, 106:16505-16510.
220. Li J., Ichikawa T., Villacorta L., Janicki J.S., Brower G.L., Yamamoto M., et al. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol 2009, 29:1843-1850.
221. Harvey C.J., Thimmulappa R.K., Sethi S., Kong X., Yarmus L., Brown R.H., et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med 2011, 3:1-10.
222. Yageta Y., Ishii Y., Morishima Y., Masuko H., Ano S., Yamadori T., et al. Role of Nrf2 in host defense against influenza virus in cigarette smoke-exposed mice. J Virol 2011, 85:4679-4690.
223. Cho H.Y., Imani F., Miller-DeGraff L., Walters D., Melendi G.A., Yamamoto M., et al. Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am J Respir Crit Care Med 2009, 179:138-150.
224. Padmanabhan B., Tong K.I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M., et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006, 21:689-700.
225. Ohta T., Iijima K., Miyamoto M., Nakahara I., Tanaka H., Ohtsuji M., et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008, 68:1303-1309.
226. Kim Y.R., Oh J.E., Kim M.S., Kang M.R., Park S.W., Han J.Y., et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010, 220:446-451.
227. Zhang P., Singh A., Yegnasubramanian S., Esopi D., Kombairaju P., Bodas M., et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010, 9:336-346.
228. Jiang T., Chen N., Zhao F., Wang X.J., Kong B., Zheng W., et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010, 70:5486-5496.
229. Rushworth S.A., Zaitseva L., Murray M.Y., Shah N.M., Bowles K.M., MacEwan D.J. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo-resistance. Blood 2012, 120:5188-5198.
230. Lister A., Nedjadi T., Kitteringham N.R., Campbell F., Costello E., Lloyd B., et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 2011, 10:1-13.
231. Sasaki H., Suzuki A., Shitara M., Hikosaka Y., Okuda K., Moriyama S., et al. Genotype analysis of the NRF2 gene mutation in lung cancer. Int J Mol Med 2013, 31:1135-1138.
232. Hu X.F., Yao J., Gao S.G., Wang X.S., Peng X.Q., Yang Y.T., et al. Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev 2013, 14:5231-5235.
233. Solis L.M., Behrens C., Dong W., Suraokar M., Ozburn N.C., Moran C.A., et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010, 16:3743-3753.
234. Satoh H., Moriguchi T., Takai J., Ebina M., Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 2013, 73:4158-4168.
235. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
236. Sporn M.B., Liby K.T. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012, 12:564-571.
237. Jaramillo M.C., Zhang D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013, 27:2179-2191.
238. Wang R., An J., Ji F., Jiao H., Sun H., Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008, 373:151-154.
239. Hanada N., Takahata T., Zhou Q., Ye X., Sun R., Itoh J., et al. Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer 2012, 12:1-11.
240. Kensler T.W., Wakabayashi N. Nrf2: friend or foe for chemoprevention?. Carcinogenesis 2010, 31:90-99.
241. Xu C., Shen G., Chen C., Gelinas C., Kong A.N. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 2005, 24:4486-4495.
242. Ahmad R., Raina D., Meyer C., Kharbanda S., Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006, 281:35764-35769.
243. Karuri A.R., Huang Y., Bodreddigari S., Sutter C.H., Roebuck B.D., Kensler T.W., et al. 3H-1,2-dithiole-3-thione targets nuclear factor kappaB to block expression of inducible nitric-oxide synthase, prevents hypotension, and improves survival in endotoxemic rats. J Pharmacol Exp Ther 2006, 317:61-67.
244. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107:600-608.
245. Seidel C., Schnekenburger M., Dicato M., Diederich M. Histone deacetylase modulators provided by mother nature. Genes Nutr 2012, 7:357-367.
246. Fang M., Chen D., Yang C.S. Dietary polyphenols may affect DNA methylation. J Nutr 2007, 137:223S-228S.